Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Avecho Biotechnology Limited ( (AU:AVE) ).
Avecho Biotechnology Limited announced a change in the director’s interest notice, specifically for Dr. Gregory Collier, involving the acquisition of 6,338,595 unquoted options. This change reflects ongoing adjustments in the company’s governance and may influence stakeholder perceptions regarding the company’s strategic direction and leadership stability.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative health products for humans and animals using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM). This system, derived from Vitamin E, enhances the solubility and absorption of drugs and nutrients. Avecho’s leading product is a cannabidiol (CBD) TPM soft-gel capsule, which is currently in Phase III clinical trials for treating insomnia.
Current Market Cap: A$12.69M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.